As of November 6, 2026, Immucell Corp /De/ has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 14, 2026, naming 1 departure. The latest filing names Bryan K. Gathagan, leaving (Form 8-K, April 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Immucell Corp /De/? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Immucell Corp /De/ reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-14. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Immucell Corp /De/ files it.
Also on the record for Immucell Corp /De/
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 20, 2025 | Stake report, Schedule 13D/A, by Ejnar A. Knudsen III | 9.21% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Immucell Corp /De/ now and the warning signs.
Free to see. No signup.
Watch Immucell Corp /De/
Get an email when Immucell Corp /De/ files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Immucell Corp /De/?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Immucell Corp /De/: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immucell Corp /De/ covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-14 | Out | 2026-04-15 | 8-K, 2026-04-14 |
New leaders reset buying decisions — get the Full Report on Immucell Corp /De/: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Immucell Corp /De/, with the record behind each one.
Find candidates like senior executive at Immucell Corp /De/Every change, in the filing's words
Departing: Bryan K. Gathagan, effective 2026-04-15
At a meeting of the Board held on April 7, 2026, Mr. Gathagan tendered his retirement from the Board effective April 15, 2026.
- During the same April 7, 2026 meeting of the Board, Michael F. Brigham and Bobbi Jo Brockmann agreed not to stand for re-election as Director at the upcoming 2026 Annual Meeting of Stockholders, and tendered their resignations from the Board effective April 15, 2026.
- Mr. Brigham had served as President and CEO of the Company for more than 25 years (since February 2000) until his retirement on November 1, 2025.
- His service as a Director dates back to 1999.
- Ms. Brockman first joined the Company in January 2010, as Director of Sales and Marketing and had served as a Board member for the past 8 years and more.
- She continues to serve as the Company's Vice President of Sales and Marketing.
- (d) At its April 7, 2026 meeting, the Board elected two new Directors to join the Board effective as of April 15, 2026, as follows: Gilles Guillemette, DVM.
- Dr. Guillemette has more than 30 years of executive experience in animal health therapeutics.
- He has held executive positions at Elanco, Bayer, Henry Schein, Chewy, and Trupanion, where he had significant P&L responsibilities, led strategy, business development and finance functions, and managed regulated therapeutic operations.
- Dr. Guillemette is currently an Operating Partner at Archimed and earned his Doctor of Veterinary Medicine in Nantes, France.
Tools for this story
Each opens in a new tab, filled in for Immucell Corp /De/. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.